Pfizer execs confidently tap their top 10 blockbusters-to-be. But what are the chances of surviving PhIII, let alone hitting these big peak sales estimates?
Pfizer’s top executive team doesn’t lack for confidence.
Where many Big Pharmas would be reluctant to put a peak sales figure on their late-stage drugs, Pfizer CEO Albert Bourla has shrugged off the usual diffidence to outline where the pharma giant expects to get $15 billion-plus.
The list, outlined this week during their investor presentations, is topped by 3 drugs in the $3 billion-plus peak sales category. They are:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.